national-cancer-institute-kmvohcb-w5g-unsplash_1

First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

Betsy Goodfellow | November 9, 2023 | News story | Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer 

AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive metastatic Castration Resistant Prostate Cancer (mCRPC) treatment.

212Pb-ADVC001 is designed to bind to PSMA, a clinically validated cell surface target that is often highly expressed in prostate cancer, with the drug having already been optimised for safety and efficacy and demonstrating potential best-in-class attributes during preclinical studies.

The phase 1/2 trial is a multi-centre, open-label study which will assess the safety and efficacy of the drug candidate in patients with PSMA-positive mCRPC, aiming to find a recommended phase 2 dose. Secondary objectives include measuring dosimetry, rPFS by RECIST and PSMA PET-CT and PSA response.

Andrew Adamovich, AdvanCell’s chief executive officer, commented: “The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the company, our scientists, clinical trial sites and our patients. We believe that 212Pb is the ideal radioisotope to realise the full therapeutic power of Targeted Alpha Therapy. This promise is strongly supported by preclinical results for 212Pb-ADVC001, which demonstrate the potential for best-in-class safety and efficacy.”

Betsy Goodfellow

Related Content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …

GSK shares results from phase 3 trial for gonorrhoea treatment

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …

Latest content